Posted by Michael Wonder on 09 Feb 2023
Dapagliflozin propanediol monohydrate for the treatment of patients with chronic heart failure with preserved or mildly reduced ejection fraction
8 February 2023 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of dapagliflozin propanediol monohydrate in the NHS in England.
Dapagliflozin propanediol monohydrate is not recommended for the treatment of adults with symptomatic chronic heart failure with preserved or mildly reduced ejection fraction.
